In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains

키워드

참고문헌 (43)

1. Hentschel E, "Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer", N Engl J Med, 328, pp.308~312 (1993)
2. Suerbaum S, "Helicobacter pylori evolution and phenotypic diversification in a changing host", Nat Rev Microbiol, 5, pp.441~452 (2007)
3. Chung JW, "The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea", Hepatogastroenterology, 58, pp.246~250 (2011)
4. Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
5. Gisbert JP, "Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori", Aliment Pharmacol Ther, 34, pp.604~617 (2011)
6. Chung JW, "Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial", J Gastroenterol Hepatol, 27, pp.1675~1680 (2012)
7. 정준원, "Meta-analysis: Sequential Therapy Is Superior to Conventional Therapy for Helicobacter pylori Infection in Korea", 대한소화기학회지, 62(5), pp.267~271 (2013), 대한소화기학회
8. Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence consensus report, 2012, pp.61, 646~664
9. Ierardi E, "How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography", World J Gastroenterol, 19, pp.8168~8180 (2013)
10. Kim SY, "Antibiotic treatment for Helicobacter pylori: is the end coming", World J Gastrointest Pharmacol Ther, 6, pp.183~198 (2015)
11. Molina-Infante J, "Practical aspects in choosing a Helicobacter pylori therapy", Gastroenterol Clin North Am, 44, pp.519~535 (2015)
12. 정명호, "헬리코박터 파일로리의 3차 구제요법에서 리파부틴과 레보플록사신의 비교", 대한소화기학회지, 59(6), pp.401~406 (2012), 대한소화기학회
13. Heep M, "Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis", Antimicrob Agents Chemother, 44, pp.1075~1077 (2000)
14. Navarro-Rodriguez T, "Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study", BMC Gastroenterol, 13, pp.56~ (2013)
15. Mirzaee V, "Randomized control trial: comparison of triple therapy plus probiotic yogurt vs. standard triple therapy on Helicobacter pylori eradication", Iran Red Crescent Med J, 14, pp.657~666 (2012)
16. Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
17. Watamoto T, "Screening of pharmacologically active small molecule compounds identifies antifungal agents against Candida biofilms", Front Microbiol, 6, pp.1453~ (2015)
18. Altaf M, "Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors", Tuberculosis (Edinb), 90, pp.333~337 (2010)
19. Lucumi E, "Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay", Antimicrob Agents Chemother, 54, pp.3597~3604 (2010)
20. Che P, "The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus", Int J Clin Exp Med, 2, pp.363~373 (2009)
21. Jean B, "Performance standards for antimicrobial susceptibility testing: 25th informational supplement" (2015), Clinical and Laboratory Standards Institute
22. Morris O. Makobongo, "Nontraditional Therapies to Treat Helicobacter pylori Infection", The Journal of Microbiology, 52(4), pp.259~272 (2014), 한국미생물학회[DOI]
23. Bhunia AK, "Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells", J Biol Chem, 272, pp.15642~15649 (1997)
24. Wang Q, "Subpicomolar diphenyleneiodonium inhibits microglial NADPH oxidase with high specificity and shows great potential as a therapeutic agent for neurodegenerative diseases", Glia, 62, pp.2034~2043 (2014)
25. Aldieri E, "Classical inhibitors of NOX NAD(P)H oxidases are not specific", Curr Drug Metab, 9, pp.686~696 (2008)
26. Cho SO, "Diphenyleneiodonium inhibits the activation of mitogen-activated protein kinases and the expression of monocyte chemoattractant protein-1 in Helicobacter pylori-infected gastric epithelial AGS cells", Inflamm Res, 60, pp.501~507 (2011)
27. Cha B, "15-Deoxy-D12,14-prostaglandin J2 suppresses RANTES expression by inhibiting NADPH oxidase activation in Helicobacter pylori-infected gastric epithelial cells", J Physiol Pharmacol, 62, pp.167~174 (2011)
28. Cho SO, "Red ginseng extract inhibits the expression of MCP-1 and iNOS in Helicobacter pylori-infected gastric epithelial cells by suppressing the activation of NADPH oxidase and Jak2", Stat3, 2013, pp.150, 761~764
29. 조순옥, "Diphenyleneiodonium Inhibits Apoptotic Cell Death of Gastric Epithelial Cells Infected with Helicobacter pylori in a Korean Isolate", Yonsei Medical Journal, 56(4), pp.1150~1154 (2015), 연세대학교의과대학[DOI]
30. Tominaga K, "Evidence for cancer-associated expression of NADPH oxidase 1 (Nox1)-based oxidase system in the human stomach", Free Radic Biol Med, 43, pp.1627~1638 (2007)
31. Jones RD, "NADPH oxidase: a universal oxygen sensor", Free Radic Biol Med, 29, pp.416~424 (2000)
32. Jang SH, "Lycopene inhibits Helicobacter pylori-induced ATM", ATR-dependent DNA damage response in gastric epithelial AGS cells, 2012, pp.52, 607~615
33. World Gastroenterology Organisation, "World Gastroenterology Organisation global guideline: Helicobacter pylori in developing countries", J Clin Gastroenterol, 45, pp.383~388 (2011)
34. Furuta T, "Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan", J Gastroenterol Hepatol, 29, pp.487~493 (2014)
35. Murakami K, "Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan", J Gastroenterol, 48, pp.1128~1135 (2013)
36. Basu PP, "A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori", Am J Gastroenterol, 106, pp.1970~1975 (2011)
37. Watson JB, "pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen", Am J Gastroenterol, 106, pp.1976~1977 (2011)
38. Vale FF, "Overview of the phytomedicine approaches against Helicobacter pylori", World J Gastroenterol, 20, pp.5594~5609 (2014)
39. Lopes D, "Eradication of Helicobacter pylori: past, present and future", J Control Release, 189, pp.169~186 (2014)
40. Gao W, "Nanoparticle approaches against bacterial infections", Wiley Interdiscip Rev Nanomed Nanobiotechnol, 6, pp.532~547 (2014)
41. Erah PO, "The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection", J Antimicrob Chemother, 39, pp.5~12 (1997)
42. Labenz J, "Current role of acid suppressants in Helicobacter pylori eradication therapy", Best Pract Res Clin Gastroenterol, 15, pp.413~431 (2001)
43. Wang Q, "Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson’s disease models", Brain, 138(Pt 5), pp.1247~1262 (2015)

관련 논문AI추천